Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Serzone withdrawal sought by Public Citizen

Executive Summary

Public Citizen sues FDA to force the withdrawal of Bristol-Myers Squibb's antidepressant Serzone (nefazodone). The 1suit, filed in D.C. federal court March 15, cites a "mounting number of deaths and serious injuries from liver failure." The lawsuit follows a March 5, 2003 citizen petition from Public Citizen - supplemented in October - asking FDA to withdraw the product (2"The Pink Sheet" March 10, 2003, p. 17)...

You may also be interested in...



Public Citizen Wants Serzone Pulled; No “Unique” Benefit To Offset Risk

Bristol-Myers Squibb's Serzone offers "no unique therapeutic benefit" to justify continued marketing in light of liver toxicity concerns, Public Citizen maintains in a March 6 petition to FDA

STADA Strengthens Specialty Partnership Role Via US Filing

STADA Strengthens Specialty Partnership Role Via US Filing

US Election 2020: Trump’s Sway Over Courts Expected To Linger

Textualist judges appointed by President Trump during his term may block a potential President Biden’s attempts to shift the government’s legal policies, experts tell Medtech Insight.

UsernamePublicRestriction

Register

MT142539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel